Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
Refractory chronic cough therapy in 2026 organises around several tiers.
First-line workup: identify and treat reversible causes (gastroesophageal reflux, upper airway cough syndrome / postnasal drip, asthma, eosinophilic bronchitis, ACE inhibitor use, environmental triggers). True refractory chronic cough remains after these have been addressed.
Off-label and historical: opioids (codeine, low-dose morphine) for refractory cases; gabapentin and pregabalin for cough hypersensitivity; speech and language therapy for cough suppression techniques.
Targeted modern tier: P2X3 antagonist gefapixant is approved in selected jurisdictions for refractory chronic cough; follow-on P2X3 programs (camlipixant and others) and non-P2X3 mechanism programs (TRP channel modulators, others) are in late-stage trials.
The diagnostic-pathway and clinical-decision-support question matters. Distinguishing refractory chronic cough from underlying treatable conditions requires structured workup, and the diagnostic care pathway shapes which patients reach the targeted-therapy tier.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.
Related
- ExplainedWhat is obstructive sleep apnea?